We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

7 hedge funds and large institutions have $1.44M invested in Loncar China BioPharma ETF in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,501% more capital invested

Capital invested by funds: $90K → $1.44M (+$1.35M)

75% more funds holding

Funds holding: 4 → 7 (+3)

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$1.42M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$49.4K
3
UBS Group
UBS Group
Switzerland
+$10.3K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.47K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$1.3M +$1.42M +57,384 New
Morgan Stanley
2
Morgan Stanley
New York
$45K – – –
Bank of Montreal
3
Bank of Montreal
Ontario, Canada
$45K +$49.4K +2,000 New
UBS Group
4
UBS Group
Switzerland
$26K +$10.3K +416 +57%
Osaic Holdings
5
Osaic Holdings
Arizona
$11K +$12.4K +500 New
Citigroup
6
Citigroup
New York
$9K – – –
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$2K +$2.47K +100 New

CHNA Hedge Fund Activity: Q1 2020 in Review

7 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q1 2020, worth a combined $1.44M — up 1,501% from $90K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CHNA positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $1.42M.

  • 7 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q1 2020, up from 4 in Q4 2019.
  • Funds reported $1.44M of Loncar China BioPharma ETF stock for Q1 2020, up 1,501% quarter-over-quarter.
  • 4 funds opened new Loncar China BioPharma ETF positions in Q1 2020 and 0 closed out, a net change of +4 holders.
  • The largest Loncar China BioPharma ETF buyer in Q1 2020 was Jane Street, an estimated $1.42M added.

Based on aggregated 13F filings for Q1 2020.